PROBIOTIC PREVENTION AND TREATMENT OF COLON CANCER

• US 20140335131A1
• Filed: 05/09/2014
• Published: 11/13/2014
• Est. Priority Date: 05/10/2013
• Status: Abandoned Application

• Current Assignee: California Institute of Technology
• Original Assignee: California Institute of Technology
• Inventors: Mazmanian, Sarkis K., Lee, Yunkyung
• Application Number:
  US14/274,607
• Publication Number:
  US 20140335131A1
• Time in Patent Office: Days
• US Class Current: 424/282.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 35/741 Probiotics probiotic yeast, e.g. saccharomyces A61K36/06
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods are provided herein for preventing, delaying the onset of or reducing the progression of colorectal tumorigenesis in a subject identified as at risk of colorectal tumorigenesis, comprising adjusting the composition of gut microbiota in the subject via administering to the subject a composition comprising Bacteroides bacteria or administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising zwitterionic polysaccharide (ZPS). In another aspect, methods are provided for treating or ameliorating a colorectal cancer in a subject, comprising adjusting the composition of gut microbiota in the subject having the colorectal cancer. In a further aspect, methods are provided for relieving gastrointestinal (GI) distress of a subject having a colorectal condition, comprising: determining the colorectal condition of the subject; and relieving GI distress in the subject by adjusting the composition of gut microbiota in the subject.

Claims

1. A method for preventing, delaying the onset of or reducing the progression of colorectal tumorigenesis in a subject identified as at risk of colorectal tumorigenesis, comprising:

adjusting the composition of gut microbiota in the subject via administering to the subject a composition comprising Bacteroides bacteria.

2. The method of claim 1, wherein the Bacteroides bacteria is B. fragilis, B. thetaiotaomicron, B. vulgatus, or a mixture thereof.

3. The method of claim 1, wherein the composition is a probiotic composition, a neutraceutical composition, a pharmaceutical composition, or a mixture thereof.

4. The method of claim 1, wherein the composition is administered via fecal transplantation or oral administration.

5. The method of claim 1, wherein the composition is administered intermittently, periodically, continuously, or chronically.

6. The method of claim 1, comprising diagnosing the subject with an intestinal inflammatory condition.

7. The method of claim 6, wherein the intestinal inflammatory condition is selected from the group consisting of inflammatory bowel disease (IBD), Crohn'"'"'s disease (CD), and ulcerative colitis (UC).

8. The method of claim 1, comprising assessing the risk of colorectal tumorigenesis of the subject.

9. The method of claim 8, wherein assessing the risk of colorectal tumorigenesis of the subject comprises looking for a family history of colorectal cancer of the subject, identifying a genetic mutation associated with colorectal cancer in the subject, testing for dysbiosis in the subject, or a combination thereof.

10. The method of claim 9, wherein the dysbiosis comprises an over-representation of Proteus mirabilis and/or Klebsiella Pneumonia.

11. The method of claim 1, wherein the tumor-free time of the subject in which the composition of gut microbiota has been adjusted is increased in comparison to a reference tumor-free time in one or more subjects in which the composition of gut microbiota has not been adjusted.

12. The method of claim 1, wherein the total size of one or more tumors in the subject in which the composition of gut microbiota has been adjusted is decreased in comparison to a reference total tumor size in one or more subjects in which the composition of gut microbiota has not been adjusted.

13. The method of claim 1, wherein the total number of the tumors in the subject in which the composition of gut microbiota has been adjusted is decreased in comparison to a reference total tumor number in one or more subjects in which the composition of gut microbiota has not been adjusted.

14. A method for preventing, delaying the onset of or reducing the progression of colorectal tumorigenesis in a subject at risk of colorectal tumorigenesis, comprising:

administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising zwitterionic polysaccharide (ZPS).

15. The method of claim 14, wherein the ZPS is derived from bacteria.

16. The method of claim 14, wherein the ZPS is polysaccharide A (PSA).

17. The method of claim 14, comprising diagnosing the subject with an intestinal inflammatory condition.

18. The method of claim 17, wherein the intestinal inflammatory condition is selected from the group consisting of inflammatory bowel disease (IBD), Crohn'"'"'s disease (CD), and ulcerative colitis (UC).

19. The method of claim 14, comprising assessing the risk of colorectal tumorigenesis of the subject.

20. The method of claim 19, wherein assessing the risk of colorectal tumorigenesis of the subject comprises looking for a family history of colorectal cancer of the subject, identifying a genetic mutation associated with colorectal cancer in the subject, testing for dysbiosis in the subject, or a combination thereof.

21. The method of claim 14, wherein the tumor-free time of the subject to which the pharmaceutical composition has been administered is increased in comparison to a reference tumor-free time in one or more subjects to which the pharmaceutical composition has not been administered.

22. The method of claim 14, wherein the total size of one or more tumors in the subject to which the pharmaceutical composition has been administered is decreased in comparison to a reference total tumor size in one or more subjects to which the pharmaceutical composition has not been administered.

23. The method of claim 14, wherein the total number of one or more tumors in the subject to which the pharmaceutical composition has been administered is decreased in comparison to a reference total tumor number in one or more subjects to which the pharmaceutical composition has not been administered.

24. A method for treating or ameliorating a colorectal cancer in a subject, comprising:

adjusting the composition of gut microbiota in the subject having the colorectal cancer.

25. The method of claim 24, wherein adjusting the composition of gut microbiota of the subject comprises administering to the subject a composition comprising Bacteroides bacteria, wherein the Bacteroides bacteria is B. fragilis, B. thetaiotaomicron, B. vulgatus, or a mixture thereof.

26. The method of claim 25, wherein the composition is administered via fecal transplantation or oral administration.

27. A method for relieving gastrointestinal (GI) distress of a subject having a colorectal condition, comprising:

determining the colorectal condition of the subject; and

relieving GI distress in the subject by adjusting the composition of gut microbiota in the subject.

28. The method of claim 27, wherein the colorectal condition is a colorectal cancer.

29. The method of claim 27, wherein the colorectal condition is an intestinal inflammatory condition.